Humanwell Healthcare (Group) Co.,Ltd. (SHA:600079)

China flag China · Delayed Price · Currency is CNY
18.60
+0.01 (0.05%)
Apr 28, 2026, 3:00 PM CST
-8.10%
Market Cap 30.36B
Revenue (ttm) 23.96B
Net Income (ttm) 1.86B
Shares Out 1.63B
EPS (ttm) 1.14
PE Ratio 16.32
Forward PE 12.74
Dividend 0.48 (2.58%)
Ex-Dividend Date Aug 19, 2025
Volume 7,546,468
Average Volume 10,097,638
Open 18.56
Previous Close 18.59
Day's Range 18.54 - 18.73
52-Week Range 16.73 - 23.66
Beta 0.51
RSI 46.19
Earnings Date Mar 31, 2026

About SHA:600079

Humanwell Healthcare (Group) Co.,Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers sufentanil citrate injection, an analgesic drug for combined anesthesia; remifentanil hydrochloride injection for induction of general anesthesia and maintenance of analgesia during general anesthesia; hydromorphone hydrochloride injection for patients who require opioid analgesia; nabuphine hydrochloride injection for use as an analgesic for anesthesia induction; alfentanil hydrochloride injec... [Read more]

Sector Healthcare
Founded 1988
Employees 17,153
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600079
Full Company Profile

Financial Performance

In 2025, SHA:600079's revenue was 23.96 billion, a decrease of -5.79% compared to the previous year's 25.44 billion. Earnings were 1.86 billion, an increase of 39.53%.

Financial Statements

News

There is no news available yet.